Scientists Uncover a Surprise in the Function of Essential Genes 

Image Credit: National Human Research Institute (Flickr)

Scientists Unveil the Functional Landscape of Essential Genes

Nicole Davis | Whitehead Institute

A team of scientists at the Whitehead Institute for Biomedical Research and the Broad Institute of MIT and Harvard has systematically evaluated the functions of over 5,000 essential human genes using a novel, pooled, imaged-based screening method. Their analysis harnesses CRISPR-Cas9 to knock out gene activity and forms a first-of-its-kind resource for understanding and visualizing gene function in a wide range of cellular processes with both spatial and temporal resolution. The team’s findings span over 31 million individual cells and include quantitative data on hundreds of different parameters that enable predictions about how genes work and operate together. The new study appears in the Nov. 7 online issue of the journal Cell.

“For my entire career, I’ve wanted to see what happens in cells when the function of an essential gene is eliminated,” says MIT Professor Iain Cheeseman, who is a senior author of the study and a member of Whitehead Institute. “Now, we can do that, not just for one gene but for every single gene that matters for a human cell dividing in a dish, and it’s enormously powerful. The resource we’ve created will benefit not just our own lab, but labs around the world.”

Systematically disrupting the function of essential genes is not a new concept, but conventional methods have been limited by various factors, including cost, feasibility, and the ability to fully eliminate the activity of essential genes. Cheeseman, who is the Herman and Margaret Sokol Professor of Biology at MIT, and his colleagues collaborated with MIT Associate Professor Paul Blainey and his team at the Broad Institute to define and realize this ambitious joint goal. The Broad Institute researchers have pioneered a new genetic screening technology that marries two approaches — large-scale, pooled, genetic screens using CRISPR-Cas9 and imaging of cells to reveal both quantitative and qualitative differences. Moreover, the method is inexpensive compared to other methods and is practiced using commercially available equipment.

“We are proud to show the incredible resolution of cellular processes that are accessible with low-cost imaging assays in partnership with Iain’s lab at the Whitehead Institute,” says Blainey, a senior author of the study, an associate professor in the Department of Biological Engineering at MIT, a member of the Koch Institute for Integrative Cancer Research at MIT, and a core institute member at the Broad Institute. “And it’s clear that this is just the tip of the iceberg for our approach. The ability to relate genetic perturbations based on even more detailed phenotypic readouts is imperative, and now accessible, for many areas of research going forward.”

Cheeseman adds, “The ability to do pooled cell biological screening just fundamentally changes the game. You have two cells sitting next to each other and so your ability to make statistically significant calculations about whether they are the same or not is just so much higher, and you can discern very small differences.”

Cheeseman, Blainey, lead authors Luke Funk and Kuan-Chung Su, and their colleagues evaluated the functions of 5,072 essential genes in a human cell line. They analyzed four markers across the cells in their screen — DNA; the DNA damage response, a key cellular pathway that detects and responds to damaged DNA; and two important structural proteins, actin and tubulin. In addition to their primary screen, the scientists also conducted a smaller, follow-up screen focused on some 200 genes involved in cell division (also called “mitosis”). The genes were identified in their initial screen as playing a clear role in mitosis but had not been previously associated with the process. These data, which are made available via a companion website, provide a resource for other scientists to investigate the functions of genes they are interested in.

“There’s a huge amount of information that we collected on these cells. For example, for the cells’ nucleus, it is not just how brightly stained it is, but how large is it, how round is it, are the edges smooth or bumpy?” says Cheeseman. “A computer really can extract a wealth of spatial information.”

Flowing from this rich, multi-dimensional data, the scientists’ work provides a kind of cell biological “fingerprint” for each gene analyzed in the screen. Using sophisticated computational clustering strategies, the researchers can compare these fingerprints to each other and construct potential regulatory relationships among genes. Because the team’s data confirms multiple relationships that are already known, it can be used to confidently make predictions about genes whose functions and/or interactions with other genes are unknown.

There are a multitude of notable discoveries to emerge from the researchers’ screening data, including a surprising one related to ion channels. Two genes, AQP7 and ATP1A1, were identified for their roles in mitosis, specifically the proper segregation of chromosomes. These genes encode membrane-bound proteins that transport ions into and out of the cell. “In all the years I’ve been working on mitosis, I never imagined ion channels were involved,” says Cheeseman.

He adds, “We’re really just scratching the surface of what can be unearthed from our data. We hope many others will not only benefit from — but also build upon — this resource.”

This work was supported by grants from the U.S. National Institutes of Health as well as support from the Gordon and Betty Moore Foundation, a National Defense Science and Engineering Graduate Fellowship, and a Natural Sciences and Engineering Research Council Fellowship.

A team of scientists at the Whitehead Institute for Biomedical Research and the Broad Institute of MIT and Harvard has systematically evaluated the functions of over 5,000 essential human genes using a novel, pooled, imaged-based screening method. Their analysis harnesses CRISPR-Cas9 to knock out gene activity and forms a first-of-its-kind resource for understanding and visualizing gene function in a wide range of cellular processes with both spatial and temporal resolution. The team’s findings span over 31 million individual cells and include quantitative data on hundreds of different parameters that enable predictions about how genes work and operate together. The new study appears in the Nov. 7 online issue of the journal Cell.

“For my entire career, I’ve wanted to see what happens in cells when the function of an essential gene is eliminated,” says MIT Professor Iain Cheeseman, who is a senior author of the study and a member of Whitehead Institute. “Now, we can do that, not just for one gene but for every single gene that matters for a human cell dividing in a dish, and it’s enormously powerful. The resource we’ve created will benefit not just our own lab, but labs around the world.”

Systematically disrupting the function of essential genes is not a new concept, but conventional methods have been limited by various factors, including cost, feasibility, and the ability to fully eliminate the activity of essential genes. Cheeseman, who is the Herman and Margaret Sokol Professor of Biology at MIT, and his colleagues collaborated with MIT Associate Professor Paul Blainey and his team at the Broad Institute to define and realize this ambitious joint goal. The Broad Institute researchers have pioneered a new genetic screening technology that marries two approaches — large-scale, pooled, genetic screens using CRISPR-Cas9 and imaging of cells to reveal both quantitative and qualitative differences. Moreover, the method is inexpensive compared to other methods and is practiced using commercially available equipment.

“We are proud to show the incredible resolution of cellular processes that are accessible with low-cost imaging assays in partnership with Iain’s lab at the Whitehead Institute,” says Blainey, a senior author of the study, an associate professor in the Department of Biological Engineering at MIT, a member of the Koch Institute for Integrative Cancer Research at MIT, and a core institute member at the Broad Institute. “And it’s clear that this is just the tip of the iceberg for our approach. The ability to relate genetic perturbations based on even more detailed phenotypic readouts is imperative, and now accessible, for many areas of research going forward.”

Cheeseman adds, “The ability to do pooled cell biological screening just fundamentally changes the game. You have two cells sitting next to each other and so your ability to make statistically significant calculations about whether they are the same or not is just so much higher, and you can discern very small differences.”

Cheeseman, Blainey, lead authors Luke Funk and Kuan-Chung Su, and their colleagues evaluated the functions of 5,072 essential genes in a human cell line. They analyzed four markers across the cells in their screen — DNA; the DNA damage response, a key cellular pathway that detects and responds to damaged DNA; and two important structural proteins, actin and tubulin. In addition to their primary screen, the scientists also conducted a smaller, follow-up screen focused on some 200 genes involved in cell division (also called “mitosis”). The genes were identified in their initial screen as playing a clear role in mitosis but had not been previously associated with the process. These data, which are made available via a companion website, provide a resource for other scientists to investigate the functions of genes they are interested in.

“There’s a huge amount of information that we collected on these cells. For example, for the cells’ nucleus, it is not just how brightly stained it is, but how large is it, how round is it, are the edges smooth or bumpy?” says Cheeseman. “A computer really can extract a wealth of spatial information.”

Flowing from this rich, multi-dimensional data, the scientists’ work provides a kind of cell biological “fingerprint” for each gene analyzed in the screen. Using sophisticated computational clustering strategies, the researchers can compare these fingerprints to each other and construct potential regulatory relationships among genes. Because the team’s data confirms multiple relationships that are already known, it can be used to confidently make predictions about genes whose functions and/or interactions with other genes are unknown.

There are a multitude of notable discoveries to emerge from the researchers’ screening data, including a surprising one related to ion channels. Two genes, AQP7 and ATP1A1, were identified for their roles in mitosis, specifically the proper segregation of chromosomes. These genes encode membrane-bound proteins that transport ions into and out of the cell. “In all the years I’ve been working on mitosis, I never imagined ion channels were involved,” says Cheeseman.

He adds, “We’re really just scratching the surface of what can be unearthed from our data. We hope many others will not only benefit from — but also build upon — this resource.”

This work was supported by grants from the U.S. National Institutes of Health as well as support from the Gordon and Betty Moore Foundation, a National Defense Science and Engineering Graduate Fellowship, and a Natural Sciences and Engineering Research Council Fellowship.

Reprinted with permission from MIT News” ( http://news.mit.edu/ )

Artemis Program to Benefit Many Companies

Image Courtesy of Aerojet Rocketdyne

Billions in Artemis Program Budget Could Cause these Companies to Rocket

What companies could gain from the Artemis missions to the moon?

The multibillion-dollar Artemis program has been unfolding over the past several years. The most recent success is the 322-foot-tall Space Launch System (SLS), the most powerful rocket NASA has developed, and the Orion spacecraft. This is all designed to, in time, safely carry astronauts to the moon’s orbit and provide a platform for the U.S. to return to the moon’s surface for the first time since 1972.

The mission of Artemis One is to test a powerful NASA rocket called the Space Launch System, as well as the Orion spacecraft that the rocket will ferry into orbit. After the Florida launch, NASA plans to use the SLS rocket to direct Orion on a route around the moon, after which the vehicle’s crewless capsule will return to Earth and parachute into the Pacific Ocean. Those steps represent another trial geared toward ensuring the Orion crew module can safely bring astronauts back from orbit.

The initial mission will help set the stage for a crewed mission to the moon that NASA hopes to conduct as early as 2025. These efforts will entail higher technology and special equipment designed especially for a unique purpose. With billions being spent, investors may ask what companies may benefit. Obviously, the major contractors, then subcontractors and material suppliers.

The cost of SLS is shown above. Additionally, the cost to assemble, integrate, prepare and launch the SLS and its payloads are funded separately under Exploration Ground Systems, currently at about $600 million per year. (Source:Wikipedia)

Major Contractors

Keeping in mind that an unsuccessful launch could weigh on these companies, as much as they may be propelled by continued success, these are prime contractors. NASA’s prime contractors for the rock launch system is Aerojet Rocketdyne (AJRD), Boeing (NYSE: BA), and Northrop Grumman (NOC). As a note, AJRD showed up as one of 5 portfolio holdings of hedge fund manager Michael Burry.

Lockheed Martin (LMT) is the prime contractor on the Orion spacecraft, while NASA’s prime contractors for the rocket launch system include Redwire’s (RDW) critical sun sensor components and advanced optical imaging technologies, they will be launching on NASA’s Orion spacecraft as a part of the space agency’s Artemis One mission. Aeva Technologies (AEVA) is also involved with a LiDAR-based mobile terrain-mapping and navigation system for lunar and other planet exploration, while KULR Technology Group (KULR) has a battery safety contract with NASA to test its lithium-ion cells going into battery packs designed for the Artemis Program.

Raytheon Technologies'(RTX) was selected to advance spacewalking capabilities in low-Earth orbit and on the Moon. Goodyear Tire & Rubber (GT) has been contracted to develop tires to perform on the lunar surface.

Rocket Lab (RKLB) has been called upon to test new orbits around the moon. For communications, Lockheed Martin (LMT), Amazon (AMZN), and Cisco (CSCO) are working in conjunction to develop a new voice, AI, and tablet-based video technologies for use around the moon.

The companies being called upon is expected to grow rapidly after scientific experiments begin on the moon’s surface.

Paul Hoffman

Managing Editor, Channelchek

Sources

https://en.wikipedia.org/wiki/Space_Launch_System#:~:text=The%20Space%20Launch%20System%20(abbreviated,2022%20from%20Kennedy%20Space%20Center.

https://www.wsj.com/articles/artemis-i-launch-moon-mission-nasa-11668529576?mod=Searchresults_pos1&page=1

https://seekingalpha.com/news/3877127-nasa-is-going-to-the-moon-will-these-stocks-benefit

Telomeres and New Findings on Cancer Mortality

Image Credit: Steve Jurvetson (Flickr)

How Cancer Cells can Become Immortal – New Research Finds a Mutated Gene that Helps Melanoma Defeat the Normal Limits on Repeated Replication

A defining characteristic of cancer cells is their immortality. Usually, normal cells are limited in the number of times they can divide before they stop growing. Cancer cells, however, can overcome this limitation to form tumors and bypass “mortality” by continuing to replicate.

Telomeres play an essential role in determining how many times a cell can divide. These repetitive sequences of DNA are located at the ends of chromosomes, structures that contain genetic information. In normal cells, continued rounds of replication shorten telomeres until they become so short that they eventually trigger the cell to stop replicating. In contrast, tumor cells can maintain the lengths of their telomeres by activating an enzyme called telomerase that rebuilds telomeres during each replication.

Telomeres are protective caps at the ends of chromosomes

Telomerase is encoded by a gene called TERT, one of the most frequently mutated genes in cancer. TERT mutations cause cells to make a little too much telomerase and are thought to help cancer cells keep their telomeres long even though they replicate at high rates. Melanoma, an aggressive form of skin cancer, is highly dependent on telomerase to grow, and three-quarters of all melanomas acquire mutations in telomerase. These same TERT mutations also occur across other cancer types.

Unexpectedly, researchers found that TERT mutations could only partially explain the longevity of telomeres in melanoma. While TERT mutations did indeed extend the life span of cells, they did not make them immortal. That meant there must be something else that helps telomerase allow cells to grow uncontrollably. But what that “second hit” might be has been unclear.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Pattra Chun-On Ph.D. Candidate in Environmental and Occupational Health, University of Pittsburgh Health Sciences and Jonathan Alder Assistant Professor of Medicine, University of Pittsburgh Health Sciences.

We are researchers who study the role telomeres play in human health and diseases like cancer in the Alder Lab at the University of Pittsburgh. While investigating the ways that tumors maintain their telomeres, we and our colleagues found another piece to the puzzle: another telomere-associated gene in melanoma.

Cell Immortality Gets a Boost

Our team focused on melanoma because this type of cancer is linked to people with long telomeres. We examined DNA sequencing data from hundreds of melanomas, looking for mutations in genes related to telomere length.

We identified a cluster of mutations in a gene called TPP1. This gene codes for one of the six proteins that form a molecular complex called shelterin that coats and protects telomeres. Even more interesting is the fact that TPP1 is known to activate telomerase. Identifying the TPP1 gene’s connection to cancer telomeres was, in a way, obvious. After all, it was more than a decade ago that researchers showed that TPP1 would increase telomerase activity.

We tested whether having an excess of TPP1 could make cells immortal. When we introduced just TPP1 proteins into cells, there was no change in cell mortality or telomere length. But when we introduced TERT and TPP1 proteins at the same time, we found that they worked synergistically to cause significant telomere lengthening.

To confirm our hypothesis, we then inserted TPP1 mutations into melanoma cells using CRISPR-Cas9 genome editing. We saw an increase in the amount of TPP1 protein the cells made, and a subsequent increase in telomerase activity. Finally, we returned to the DNA sequencing data and found that 5% of all melanomas have a mutation in both TERT and TPP1. While this is still a significant proportion of melanomas, there are likely other factors that contribute to telomere maintenance in this cancer.

Our findings imply that TPP1 is likely one of the missing puzzle pieces that boost telomerase’s capacity to maintain telomeres and support tumor growth and immortality.

Making Cancer Mortal

Knowing that cancer use these genes in their replication and growth means that researchers could also block them and potentially stop telomeres from lengthening and make cancer cells mortal. This discovery not only gives scientists another potential avenue for cancer treatment but also draws attention to an underappreciated class of mutations outside the traditional boundaries of genes that can play a role in cancer diagnostics.

Blockchain and Web 3 Communities Get More Visibility Into Their Networks

Image Credit: Dejan Krsmanovic (Flickr)

Helping Blockchain Communities Fix Bugs

Zach Winn | MIT News Office

If the crypto enthusiasts are right, the next decade will see billions of people begin using applications built off distributed, user-owned blockchains. The new paradigm has been dubbed Web 3. But Web 3 still has some significant challenges to overcome if it’s going to replace the digital world as we know it.

Blockchain networks, for instance, are going to need an efficient way of detecting and resolving performance problems. Current analytics tools are built for companies to monitor their websites and apps. Such services need only be designed for one user. In the decentralized world of the blockchains, however, the users are the owners, turning the traditional model of maintenance and bug fixes on its head.

The company Metrika, founded by an MIT alumnus, has developed a suite of tools to help the distributed communities of the blockchain world monitor and improve their networks. The company allows users to create alerts, access reports, and view real-time community dashboards that visualize network performance, problems, and trends over time.

“Metrika is a community-based monitoring and collaboration platform,” founder and CEO Nikos Andrikogiannopoulos SM ’06, MBA ’11 says. “We’re making [blockchain network] telemetry a public good for everyone. These applications are holding billions of dollars in assets, so it’s unimaginable that we wouldn’t have service assurance and deep visibility of what is happening in real-time.”

Metrika is currently providing services for popular blockchain protocols including Ethereum, Algorand, Flow, and Solana. The company plans to expand that list as other networks grow in popularity in hopes of enabling the much-hyped shift to Web 3.

“Our vision at Metrika is to become a critical layer of the Web 3 world,” Andrikogiannopoulos says. “Ten years from now, kids will be interacting with assets on their mobile phone. The idea of a bank account will be foreign to them. There will be no corner banks. The whole idea of finance will not go through physical stores and bank accounts — you’ll have assets on every application you use. In that world, where everything is happening on a blockchain, how can Metrika help provide the observability, reliability, and visibility of the blockchain network?”

Bouncing Ideas Off MIT

Andrikogiannopoulos first came to MIT as a graduate student in 2004 and he likes to say he never really left. To this day he lives in Cambridge with his wife, who works at MIT, and returns to campus often.

After earning his second MIT degree, an MBA from the Sloan School of Management, Andrikogiannopoulos began a telecommunications consulting job. During lunch breaks, he’d return to MIT to work with the Venture Mentoring Services (VMS), where entrepreneurs from the MIT community can connect with mentors and receive advice. While kicking around telecommunications startup ideas, a VMS mentor connected him to internet entrepreneur Rubin Gruber, who suggested he explore the blockchain space instead.

It was mid 2018 — what many remember as the “crypto winter” for the lull in blockchain hype and the corresponding crash of crypto prices. But Andrikogiannopoulos began researching the industry and networking with people in the blockchain space, including an MIT alumnus working at the blockchain company Algorand, which was founded by Silvio Micali, the Ford Foundation Professor of Engineering at MIT.

A few months after their initial talk, Andrikogiannopoulos returned to Gruber’s office and told him blockchains were lacking monitoring and operational intelligence.

The problem stems from the decentralized structure of blockchains. Each user operates as a node in the system by creating, receiving, and moving data through their server. When users encounter a problem, they need to figure out if the problem lies within their node or involves the network as a whole.

“They might go on Twitter and Discord and ask other users what they’re experiencing,” Andrikogiannopoulos says. “They’re trying to triangulate the problem, and it takes several hours for them to figure out the issue, coordinate a response, and resolve it.”

To build Metrika, Andrikogiannopoulos set up open-source nodes across the globe that pull data from the nodes and networks, then aggregate those data into easy-to-understand reports and other tools.

“We act as public infrastructure, so users get visibility through dashboards, alerting, and reports, and then we add collaboration tools on top of that,” Andrikogiannopoulos explains.

By 2019, Metrika had begun detecting problems with node performance, staking, network latency, and errors like blocks not being produced at the right rate. Andrikogiannopoulos showed his progress to employees at Algorand, who expressed interest, so he continued building out Metrika’s suite of tools.

“You can see the idea of Metrika bounced across the entire MIT ecosystem,” Andrikogiannopoulos says. “It’s crucial when you start companies that you have these kinds of insight and resource-rich environments like MIT, where you can iterate on your ideas and find team members to join you.”

Enabling Web 3

Blockchains are no longer a niche technology. Around the world, companies in finance and logistics, as well gamers and other creatives, are adopting the technology.

“The blockchain world up to today has been a large experiment,” Andrikogiannopoulos says. “A lot of this infrastructure just hasn’t been built. But Bitcoin proved this can work outside of the traditional finance world, and Ethereum is bringing it to another level with applications, smart contracts, and by creating essentially a decentralized, smart computer. We think about enabling that world we see coming.”

As Metrika continues building out solutions to monitor blockchains, it also wants to offer services for the many applications being built on top of that infrastructure.

“In the future, if a blockchain transaction doesn’t go through and you’re Goldman Sachs or JP Morgan, you need to know why that transaction didn’t go through and what happened,” Andrikogiannopoulos says. “Or if you’re an application playing a game or buying assets and the transactions are lagging, you need to understand why the user experience is being impacted. In Web 3 these things are every important because of the scale and the flow of value we’re talking about.”

For Nikos, improving blockchain performance is not just about optimizing networks. It’s also about helping to usher in the world of open finance and open applications that Web 3 promises.

“We’ve reached 17 hours of outage on blockchain networks in some cases, but what’s even more important to me is not the outages themselves, but the infrastructure needed to avoid them as the industry continues maturing,” Nikos says. “These problems can compromise trust as we’re onboarding users into the Web 3 world. Metrika’s mission is to enable a compelling Web 3 ecosystem.”

October’s Stock Market Performance Has a Valuable Lesson

Image Credit: Jordan Doane (500px.com)

Looking Back at October and Forward to Year-End 2022

The stock market for October was a home run for many industries. In fact, only a few market sectors were negative, each by less than one percent. After a losing first three quarters in most categories, investors are now asking, are we out of the losing slump? Did I already miss the best plays? There are still two months left in 2022, and there are a number of expected events that could cause high volatility (up/down). If you’ve been a market spectator, you want to know, should I get on the field and maybe take advantage of this streak? If you’ve been involved and are now at a recent high, you may instead consider taking a seat for the last two months.

Let’s look back and then forward as we enter the final two months of the year. Below we look at the month behind us in stocks, gold, and crypto. There is something that may be unfolding is stocks that is worth steering around.

Major Market Indexes for October

Source: Koyfin

Large industrials, as measured by the Dow 30, had the best comparative performance in October. In fact, the Dow had its best month since 1976. Some investors have been rotating out of large high-tech and into more traditional businesses, like large industrial companies. Another reason it has gotten attention is of the 30 stocks in the Dow Industrials, at least 27 are expected to pay dividends; the lower stock prices from months of decline have raised the expected dividend yields to levels where investors are finding value and doing some reallocating. For example, Dow Chemicals (DOW)with a yield near 5% (plus any appreciations) or Verizon (VZ) at 7% can be appealing, especially for assets of retirees.

The small-cap stocks, as measured by the Russell 2000, weren’t far behind the Dow 30. This group has been lagging for some time and, by many measures, including price/earnings, offers value, while many larger stocks are still considered overpriced. Another thing working in favor of small U.S.-based companies is a likely customer universe that is not hurt by a strong dollar and international trade. In fact, there are small companies that can be shown to have benefitted from a strong native currency and have a competitive advantage with lower borrowing needs. Many analysts expect continued outperformance of the small-cap sector as it offers value and less global disruption.

The top 500 largest stocks, as measured by the S&P 500, had a very good month but are being dragged down by the large weighting of a few huge companies that the market feels have gotten way ahead of where they should be reasonably priced. The Nasdaq 100, shown above as returning only around 3.6%, has been hurt by this index weighting as well. These indexes had once benefitted from these few stocks flying high during the pandemic; the post-pandemic world, as well as global headwinds, are now working against them.

Major Market Indexes Through 10/2022

Source: Koyfin

Investors have been taught that index funds and ETFs provide diversification, but that has never been true of Dow-indexed funds (30 stocks). And the S&P and Nasdaq 100, with heavy weightings in a few companies, only give the illusion of broad exposure. The S&P 500 and Nasdaq 100 relative performance during October may cause more investors to consider hand-selecting companies with lower P/Es, lower global exposure, and higher growth potential.

Sectors Within S&P Index

Source: Koyfin

Oil companies regained their lead as they have been a sector detached from other stocks since late 2019. The industrial sector was second and followed by the only other industry above double digits, finance. Most (not all) financial companies benefit from higher interest rates, and those that take deposits (short-term) and lend money (long-term) do best with a steep yield curve.

On the bottom of the list are consumer discretionary companies, which are hurt by the strong dollar and a weakening economy; this sector is followed by communication. Communication is worth a deeper dive as it exemplifies how the weighting of stocks in popular indexes can hurt index returns – some say high-flying, highly weighted stocks are even in a bubble.

Below the chart compares two names in the S&P 500 that are also represented in the communications index. Meta (META) is 17.70% of the index and is down 30% in October. AT&T (T) is 4.70% of the communications index; it returned nearly 20% for the month. The funds weighting methodology that worked to the advantage of index investors, until it didn’t, has worked against some index investors.

Source: Koyfin

There is a rivalry of sorts between larger, more accepted cryptocurrencies and gold. Gold wants to regain its centuries-old place as the hard asset that best represents safety, even in the worst conditions, and Bitcoin or Ether, which is looking for respect, as the alternative asset that represents safety.

Crypto has been loosely moving in the same direction as stocks all year. October was no exception, as its price per dollar rose significantly during the month. Gold, despite much worry in the world, continued a slow downtrend.

Gold and Bitcoin Performance

Source: Koyfin

Take Away

Stock market participants that held on finally got a month where it was hard not to come out ahead. The question now is, do you take the gains and sit tight while the fed tightening, election, war, and global recession settle? Or do you look at the current dynamics and allocate where the highest probability of success lies? Maybe small-cap value stocks or oil and gas companies.

There is one thing investors have been warned about repeatedly over the years by well-respected investors, including Michael Burry. There is a risk inherent in indexes now that a few extremely “overpriced” stocks represent a large percentage of index funds.

Investors evaluating smaller, individual stocks have found the data and analysis on Channelchek to be indispensable. Be sure to sign-up for Channelchek at no cost to receive unbiased research on companies that are less talked about, but may have a place in your portfolio mix.

Paul Hoffman

Managing Editor, Channelchek

Sources

https://home.treasury.gov/news/press-releases/jy1062

https://indexarb.com/dividendYieldSorteddj.html

https://www.marketwatch.com/investing/fund/xlc/holdings

$1.8 Billion Cancer “Moonshot” includes MCED Development

Image Credit: Karolina Grawbowska (Pexels)

A Blood Test that Screens for Multiple Cancers at Once Promises to Boost Early Detection

Detecting cancer early before it spreads throughout the body can be lifesaving. This is why doctors recommend regular screening for several common cancer types, using a variety of methods. Colonoscopies, for example, screen for colon cancer, while mammograms screen for breast cancer.

While important, getting all these tests done can be logistically challenging, expensive and sometimes uncomfortable for patients. But what if a single blood test could screen for most common cancer types all at once?

This is the promise of multicancer early detection tests, or MCEDs. This year, President Joe Biden identified developing MCED tests as a priority for the Cancer Moonshot, a US$1.8 billion federal effort to reduce the cancer death rate and improve the quality of life of cancer survivors and those living with cancer.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Colin Pritchard, Professor of Laboratory Medicine and Pathology, University of Washington.

As a laboratory medicine physician and researcher who develops molecular tests for cancer, I believe MCED tests are likely to transform cancer screening in the near future, particularly if they receive strong federal support to enable rapid innovation.

How MCED Tests Work

All cells in the body, including tumor cells, shed DNA into the bloodstream when they die. MCED tests look for the trace amounts of tumor DNA in the bloodstream. This circulating “cell-free” DNA contains information about what type of tissue it came from and whether it is normal or cancerous.

Testing to look for circulating tumor DNA in the blood is not new. These liquid biopsies – a fancy way of saying blood tests – are already widely used for patients with advanced-stage cancer. Doctors use these blood tests to look for mutations in the tumor DNA that help guide treatment. Because patients with late-stage cancer tend to have a large amount of tumor DNA circulating in the blood, it’s relatively easy to detect the presence of these genetic changes.

MCED tests are different from existing liquid biopsies because they are trying to detect early-stage cancer, when there aren’t that many tumor cells yet. Detecting these cancer cells can be challenging early on because noncancer cells also shed DNA into the bloodstream. Since most of the circulating DNA in the bloodstream comes from noncancer cells, detecting the presence of a few molecules of cancer DNA is like finding a needle in a haystack.

Making things even more difficult, blood cells shed abnormal DNA naturally with aging, and these strands can be confused for circulating cancer DNA. This phenomenon, known as clonal hematopoiesis, confounded early attempts at developing MCED tests, with too many false positive results.

Fortunately, newer tests are able to avoid blood cell interference by focusing on a type of “molecular barcode” embedded in the cancer DNA that identifies the tissue it came from. These barcodes are a result of DNA methylation, naturally existing modifications to the surface of DNA that vary for each type of tissue in the body. For example, lung tissue has a different DNA methylation pattern than breast tissue. Furthermore, cancer cells have abnormal DNA methylation patterns that correlate with cancer type. By cataloging different DNA methylation patterns, MCED tests can focus on the sections of DNA that distinguish between cancerous and normal tissue and pinpoint the cancer’s origin site.

DNA contains molecular patterns that indicate where in the body it came from. (CNX OpenStax/Wikimedia Commons)

Testing Options

There are currently several MCED tests in development and in clinical trials. No MCED test is currently FDA-approved or recommended by medical societies.

In 2021, the biotech company GRAIL, LLC launched the first commercially available MCED test in the U.S. Its Galleri test claims to detect over 50 different types of cancers. At least two other U.S.-based companies, Exact Sciences and Freenome, and one Chinese company, Singlera Genomics, have tests in development. Some of these tests use different cancer detection methods in addition to circulating tumor DNA, such as looking for cancer-associated proteins in blood.

MCED tests are not yet typically covered by insurance. GRAIL’s Galleri test is currently priced at $949, and the company offers a payment plan for people who have to pay out of pocket. Legislators have introduced a bill in Congress to provide Medicare coverage for MCED tests that obtain FDA approval. It is unusual for Congress to consider legislation devoted to a single lab test, and this highlights both the scale of the medical market for MCED and concerns about disparities in access without coverage for these expensive tests.

How Should MCED Tests be Used?

Figuring out how MCED tests should be implemented in the clinic will take many years. Researchers and clinicians are just beginning to address questions on who should be tested, at what age, and how past medical and family history should be taken into account. Setting guidelines for how doctors will further evaluate positive MCED results is just as important.

There is also concern that MCED tests may result in overdiagnoses of low-risk, asymptomatic cancers better left undetected. This happened with prostate cancer screening. Previously, guidelines recommended that all men ages 55 to 69 regularly get blood tests to determine their levels of PSA, a protein produced by cancerous and noncancerous prostate tissue. But now the recommendation is more nuanced, with screening suggested on an individual basis that takes into account personal preferences.

Another concern is that further testing to confirm positive MCED results will be costly and a burden to the medical system, particularly if a full-body scan is required. The out-of-pocket cost for an MRI, for example, can run up to thousands of dollars. And patients who get a positive MCED result but are unable to confirm the presence of cancer after extensive imaging and other follow-up tests may develop lifelong anxiety about a potentially missed diagnosis and continue to take expensive tests in fruitless search for a tumor.

Despite these concerns, early clinical studies show promise. A 2020 study of over 10,000 previously undiagnosed women found 26 of 134 women with a positive MCED test were confirmed to have cancer. A 2021 study sponsored by GRAIL found that half of the over 2,800 patients with a known cancer diagnosis had a positive MCED test and only 0.5% of people confirmed to not have cancer had a false positive test. The test performed best for patients with more advanced cancers but did detect about 17% of the patients who had very-early-stage disease.

MCED tests may soon revolutionize the way clinicians approach cancer screening. The question is whether the healthcare system is ready for them.

Stem Cell Research is Helping to Understand Reproductive Risks in Space

Image Credit: Karl Schultz

Pregnancy in Space: Studying Stem Cells in Zero Gravity May Determine Whether it’s Safe

Space is a hostile, extreme environment. It’s only a matter of time before ordinary people are exposed to this environment, either by engaging in space tourism or by joining self-sustaining colonies far away from Earth.

To this end, there needs to be a much better understanding of how the environmental dangers of space will affect the biology of our cells, tissues, organs, and cognition. Crucially for future space colonies, we need to know whether we can easily reproduce in environments other than those found on Earth.

The effects of radiation on our cells, producing DNA damage, are well documented. What’s less clear is how lower levels of gravity, what scientists call microgravity, will affect the mechanisms and rhythms taking place within our cells.

Scientists are only just beginning to investigate how activity in our cells might be affected by exposure to microgravity. Crucially, experiments on embryonic stem cells, and models of how embryos develop in their first few weeks in space, will help us determine whether it’s possible for humans to produce offspring in the extraplanetary colonies of the future.

Cosmic Conception

The ability to reproduce in space has been assessed in a few animals, including insects, amphibians, fish, reptiles, birds, and rodents. They have found that it’s certainly possible for organisms such as fish, frogs and geckos to produce fertilised eggs during spaceflight that can live and reproduce on Earth.

But the picture is more complicated in mammals. A study of mice, for instance, found that their oestrous cycle, part of the reproductive cycle, was disrupted by exposure to microgravity. Another study found that exposure to microgravity caused negative neurological alterations in rats. Hypothetically, these effects could also be transmitted to subsequent generations.

This likely happens because our cells did not evolve to work in microgravity. They evolved over millions of years on Earth, in it’s unique gravitational field. Earth’s gravity is part of what anchors and exerts physical force on our tissues, our cells, and our intracellular contents, helping to control specific movements within cells. The study of this is called mechanobiology.

The division of cells and the movement of genes and chromosomes within them, which is crucial to the development of a foetus, also works with and against the force of gravity as we know it on Earth. It follows that systems evolved to work perfectly in Earth’s gravity may be affected when the force of gravity changes.

Fetal Position

When an embryo first starts to divide, in a process called cleavage, the rate of division can be faster at one end of the embryo than the other. Gravity plays a role here, determining the position of the very first building blocks in a human life.

gravity also helps to establish the correct body plan of a fetus, ensuring the right cells develop in the right places in the right numbers and in the right spatial orientation.

Researchers have investigated whether embryonic stem cells, which are “pluripotent” and can develop into all cells of the body, are affected by microgravity. At present, there is some evidence that when rodent embryonic stem cells are subjected to microgravity, their ability to become the desired cell types may be impacted.

It is also possible to produce pluripotent human stem cells from normal mature cells of our bodies, which are called induced pluripotent stem cells. These have also been studied under microgravity, with experiments on Earth finding that induced stem cells proliferate faster in simulated microgravity. Two batches of these stem cells are currently on the International Space Station to see whether these results can be replicated in space.

If adult stem cells do proliferate faster in space, it could open the door for commercial stem cell manufacturers to produce these cells in orbit, seeing as it’s difficult to culture enough stem cells on Earth to treat degenerative diseases with stem cell therapies.

Gravitational Field

Besides normal cellular processes, it’s also unclear how fertilization, hormone production, lactation, and even birth itself will be affected by exposure to microgravity.

It seems that short-term exposure to microgravity, of perhaps half an hour, will probably not have too much of an effect on our cells. But longer exposures of days or weeks are likely to have an effect. This is not taking into account the effect of radiation on our cells and DNA, but we already know how to protect against radiation.

Scientists are looking at two ways to protect against the adverse effects of microgravity on our biology: intervention at the cellular level, using drugs or nanotechnology, and intervention on the environmental level, by simulating Earth’s gravity in spacecraft or off-world colonies. Both fields of study are in their early stages.

Still, studying stem cells in space provides a valuable window into how pregnancy could work, or not work when we’re outside Earth’s gravitational field. For now, those fortunate enough to go to space might do well to avoid attempting to conceive before, during or directly after a space flight.

Less Expensive Batteries Don’t Always Come from Cheaper Materials

Image Credit: 24M Technology (MIT News)

Zach Winn | MIT News Office

When it comes to battery innovations, much attention gets paid to potential new chemistries and materials. Often overlooked is the importance of production processes for bringing down costs.

Now the MIT spinout 24M Technologies has simplified lithium-ion battery production with a new design that requires fewer materials and fewer steps to manufacture each cell. The company says the design, which it calls “SemiSolid” for its use of gooey electrodes, reduces production costs by up to 40 percent. The approach also improves the batteries’ energy density, safety, and recyclability.

Judging by industry interest, 24M is onto something. Since coming out of stealth mode in 2015, 24M has licensed its technology to multinational companies including Volkswagen, Fujifilm, Lucas TVS, Axxiva, and Freyr. Those last three companies are planning to build gigafactories (factories with gigawatt-scale annual production capacity) based on 24M’s technology in India, China, Norway, and the United States.

“The SemiSolid platform has been proven at the scale of hundreds of megawatts being produced for residential energy-storage systems. Now we want to prove it at the gigawatt scale,” says 24M CEO Naoki Ota, whose team includes 24M co-founder, chief scientist, and MIT Professor Yet-Ming Chiang.

Establishing large-scale production lines is only the first phase of 24M’s plan. Another key draw of its battery design is that it can work with different combinations of lithium-ion chemistries. That means 24M’s partners can incorporate better-performing materials down the line without substantially changing manufacturing processes.

The kind of quick, large-scale production of next-generation batteries that 24M hopes to enable could have a dramatic impact on battery adoption across society — from the cost and performance of electric cars to the ability of renewable energy to replace fossil fuels.

“This is a platform technology,” Ota says. “We’re not just a low-cost and high-reliability operator. That’s what we are today, but we can also be competitive with next-generation chemistry. We can use any chemistry in the market without customers changing their supply chains. Other startups are trying to address that issue tomorrow, not today. Our tech can address the issue today and tomorrow.”

A Simplified Design

Chiang, who is MIT’s Kyocera Professor of Materials Science and Engineering, got his first glimpse into large-scale battery production after co-founding another battery company, A123 Systems, in 2001. As that company was preparing to go public in the late 2000s, Chiang began wondering if he could design a battery that would be easier to manufacture.

“I got this window into what battery manufacturing looked like, and what struck me was that even though we pulled it off, it was an incredibly complicated manufacturing process,” Chiang says. “It derived from magnetic tape manufacturing that was adapted to batteries in the late 1980s.”

In his lab at MIT, where he’s been a professor since 1985, Chiang started from scratch with a new kind of device he called a “semi-solid flow battery” that pumps liquids carrying particle-based electrodes to and from tanks to store a charge.

In 2010, Chiang partnered with W. Craig Carter, who is MIT’s POSCO Professor of Materials Science and Engineering, and the two professors supervised a student, Mihai Duduta ’11, who explored flow batteries for his undergraduate thesis. Within a month, Duduta had developed a prototype in Chiang’s lab, and 24M was born. (Duduta was the company’s first hire.)

But even as 24M worked with MIT’s Technology Licensing Office (TLO) to commercialize research done in Chiang’s lab, people in the company including Duduta began rethinking the flow battery concept. An internal cost analysis by Carter, who consulted for 24M for several years, ultimately lead the researchers to change directions.

That left the company with loads of the gooey slurry that made up the electrodes in their flow batteries. A few weeks after Carter’s cost analysis, Duduta, then a senior research scientist at 24M, decided to start using the slurry to assemble batteries by hand, mixing the gooey electrodes directly into the electrolyte. The idea caught on.

The main components of batteries are the positive and negatively charged electrodes and the electrolyte material that allows ions to flow between them. Traditional lithium-ion batteries use solid electrodes separated from the electrolyte by layers of inert plastics and metals, which hold the electrodes in place.

Stripping away the inert materials of traditional batteries and embracing the gooey electrode mix gives 24M’s design a number of advantages.

For one, it eliminates the energy-intensive process of drying and solidifying the electrodes in traditional lithium-ion production. The company says it also reduces the need for more than 80 percent of the inactive materials in traditional batteries, including expensive ones like copper and aluminum. The design also requires no binder and features extra thick electrodes, improving the energy density of the batteries.

“When you start a company, the smart thing to do is to revisit all of your assumptions  and ask what is the best way to accomplish your objectives, which in our case was simply-manufactured, low-cost batteries,” Chiang says. “We decided our real value was in making a lithium-ion suspension that was electrochemically active from the beginning, with electrolyte in it, and you just use the electrolyte as the processing solvent.”

In 2017, 24M participated in the MIT Industrial Liaison Program’s STEX25 Startup Accelerator, in which Chiang and collaborators made critical industry connections that would help it secure early partnerships. 24M has also collaborated with MIT researchers on projects funded by the Department of Energy.

Enabling the Battery Revolution

Most of 24M’s partners are eyeing the rapidly growing electric vehicle (EV) market for their batteries, and the founders believe their technology will accelerate EV adoption. (Battery costs make up 30 to 40 percent of the price of EVs, according to the Institute for Energy Research).

“Lithium-ion batteries have made huge improvements over the years, but even Elon Musk says we need some breakthrough technology,” Ota says, referring to the CEO of EV firm Tesla. “To make EVs more common, we need a production cost breakthrough; we can’t just rely on cost reduction through scaling because we already make a lot of batteries today.”

24M is also working to prove out new battery chemistries that its partners could quickly incorporate into their gigafactories. In January of this year, 24M received a grant from the Department of Energy’s ARPA-E program to develop and scale a high-energy-density battery that uses a lithium metal anode and semi-solid cathode for use in electric aviation.

That project is one of many around the world designed to validate new lithium-ion battery chemistries that could enable a long-sought battery revolution. As 24M continues to foster the creation of large scale, global production lines, the team believes it is well-positioned to turn lab innovations into ubiquitous, world-changing products.

“This technology is a platform, and our vision is to be like Google’s Android [operating system], where other people can build things on our platform,” Ota says. “We want to do that but with hardware. That’s why we’re licensing the technology. Our partners can use the same production lines to get the benefits of new chemistries and approaches. This platform gives everyone more options.”

Reprinted with permission of MIT News  ( http://news.mit.edu/)

Blackboxstocks (BLBX) – Unsettled Markets Impacting Results


Tuesday, October 18, 2022

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/video feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com .

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3Q22 Revenue Guidance. Late last week Blackboxstocks management announced that revenue for the third quarter, ended September 30, 2022, will be between $1.15 million and $1.25 million, which is below the $1.4 million of revenue reported in the second quarter of 2022 and would be the lowest level of reported revenue in over seven quarters.

Poor Stock Market Performance. The poor performance of the overall stock market over an extended period has impacted new customer acquisition as retail traders have become increasingly hesitant to enter the markets. However, with the new products scheduled to be released in 2023 in Stock Nanny and the Pro version of the Company’s product, we believe the products will expand on the Company’s TAM while also regaining its lost subscriber momentum.


Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Michael Burry Wonders Aloud if Facebook Knows What It Wants to Be

Image Credit: Marco Verch (Flickr)  

Is Meta the Wrong Path for Facebook, or is it Just Ahead of its Time?

Not all ideas are good ideas, even when they come from billionaire tech start-up founders like Mark Zuckerberg.

Michael Burry, the legendary investor of “Big Short” fame, has been criticizing the social media giant’s metaverse strategy. Burry joins others in questioning why Zuck would change the Facebook formula and spend billions embracing something that is far from real. Many of Zuckerberg’s critics are other successful billionaires like Elon Musk and Mark Cuban. Other critics are investors that have endured Meta share’s 62.3% ($570 billion) decline since January.  

Burry founded and manages the hedge fund Scion Asset Management. Burry tweeted a message that seems to say Meta management blew it – and suggests they have blown it by historic proportions by taking a deep dive into something that may or may not have legs – the metaverse.

Image: @BurryDeleted (Twitter)

You don’t have to have been alive in the mid-1980s to know what Burry was saying when he posted, “Seems Meta has a New Coke problem.” Any business school textbook lists Coca-Cola’s changing the formula of its best-selling product as the #1 lesson in corporate blunders. It was an expensive change that failed miserably and caused the company to revert back to its original product or risk losing a lot more ground against rivals.

A Sweet Refresher

New Coke was a much sweeter version of the Coca-Cola people had become accustomed to using to wash down their pizza slices, or a burger and fries. It was introduced by Coca-Cola in April 1985 during the cola war Pepsi was waging.

At the time Coca Cola was perhaps one of the most recognized brands in the world. But, Pepsi stole customers after it ran a few Michael Jackson commercials suggesting its sugar water was the “choice of a new generation,” and also backed it up with ads showing blind taste test preferences. Between the taste test science and everyone wanting to be more like Michael Jackson, Coke lost market share. Coke reacted by reformulating its product and did its own blind side-by-side tests that indicated that consumers seemed to prefer the new sweeter taste, similar to Pepsi. The company then decided to market the reformulated recipe – New Coke was born.

Max Headroom was the spokesman for New Coke, Like the Grand Canyon (Flickr)

New Coke was introduced in April 1985, and within weeks they were receiving 5,000 angry calls a day. The number grew from there. Seventy-nine days after their initial announcement, Coca-Cola held a press conference in July 1985 to offer a mea culpa and announce the return of the original Coca-Cola “classic” formula.

Will Zuckerberg Relent?

So far, Facebook, I mean Meta, still wants to identify as a metaverse company, despite there being very few metaverse customers. The company is making sure users have accessories available and just unveiled a new virtual reality headset selling for $1,500 called the Meta Quest Pro. Zuckerberg says lower priced, presumably not “pro,” will follow ($300-$500 zone).

When one has built a business from a college dorm, a garage, or their mother’s basement, and it attains the kind of growth that Facebook, Apple, Amazon, or others have, it’s hard to keep growing at the pace investors and other onlookers have become accustomed to. This leads to a scenario where investors are exposed to a risk best described as the bigger they are, the farther they have to fall.  

And Facebook has fallen, not just in dollar value, but in ranking among its peers. Does this mean Zuckerberg is not right? The game isn’t over, and there aren’t many of us that can say, with honesty, that we are more forward-looking or have more luck than Zuck.

Is Michael Burry Right?

There is a whole universe of stocks beyond metaverse investments. Huge successful companies like Facebook or even Coca-Cola have ample resources to build and grow but lose nimbleness and growth potential, unlike the potential smaller companies enjoy. Huge companies are also more likely to have a “say yes to the boss, and you’ll be rewarded” culture, rather than a small company culture which is more “show the boss you can make them money, and you’ll be rewarded” culture.

Zuckerberg and Meta may very well be moving forward with a mistake that could be enshrined in textbooks years from now. However, like Coke, they may find that if it’s a lemon, they can make lemonade. Coca-Cola emerged from the brief departure from their main product strengthened as consumers discovered what life was like without their favorite soft drink.

Take Away

Michael Burry is worth paying attention to. He thinks differently and has been correct enough to always listen. The metaverse is new; does this mean it won’t grow and become something only a visionary like Mark Zuckerberg can imagine? It has been an expensive and slow start. I suspect Facebook was much less expensive to get off the ground, and adoption also required ancillary products to be useable by the masses.

A lesson investors should remember from this is how difficult it is for large companies to grow from their current offerings and huge corporate base.

Channelchek is a platform created to help investors uncover the next Apple, the next Moderna, or the next Facebook. It’s a resource to dig deeper into these less celebrated fledgling opportunities and to leave investors with enough understanding to decide whether they should take their own action by buying stock and becoming an owner of something with greater than average potential.

Paul Hoffman

Managing Editor, Channelchek  

Sources

https://www.history.com/news/why-coca-cola-new-coke-flopped

https://www.thestreet.com/technology/big-short-burry-says-facebook-and-zuckerberg-are-in-big-trouble

https://www.nytimes.com/2022/10/09/technology/meta-zuckerberg-metaverse.html

Medical Device Improves Muscle Rehab Accuracy by 15%

Image Credit: MIT CSAIL

MIT System “Sees” the Inner Structure of the Body During Physical Rehab

Rachel Gordon | MIT CSAIL

A growing number of people are living with conditions that could benefit from physical rehabilitation — but there aren’t enough physical therapists (PTs) to go around. The growing need for PTs is racing alongside population growth, and aging, as well as higher rates of severe ailments, are contributing to the problem.

An upsurge in sensor-based techniques, such as on-body motion sensors, has provided some autonomy and precision for patients who could benefit from robotic systems to supplement human therapists. Still, the minimalist watches and rings that are currently available largely rely on motion data, which lack more holistic data a physical therapist pieces together, including muscle engagement and tension, in addition to movement.

This muscle-motion language barrier recently prompted the creation of an unsupervised physical rehabilitation system, MuscleRehab, by researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Massachusetts General Hospital. There are three ingredients: motion tracking that captures motion activity, an imaging technique called electrical impedance tomography (EIT) that measures what the muscles are up to, and a virtual reality (VR) headset and tracking suit that lets a patient watch themselves perform alongside a physical therapist.

Patients put on the sleek ninja-esque all-black tracking suit and then perform various exercises such as lunges, knee bends, dead lifts, leg raises, knee extensions, squats, fire hydrants, and bridges that measure activity of quadriceps, sartorius, hamstrings, and abductors. VR captures 3D movement data.

In the virtual environment, patients are given two conditions. In both cases, their avatar performs alongside a physical therapist. In the first situation, just the motion tracking data is overlaid onto their patient avatar. In the second situation, the patient puts on the EIT sensing straps, and then they have all the information of the motion and muscle engagement.

With these two conditions, the team compared the exercise accuracy and handed the results to a professional therapist, who explained which muscle groups were supposed to be engaged during each of the exercises. By visualizing both muscle engagement and motion data during these unsupervised exercises instead of just motion alone, the overall accuracy of exercises improved by 15 percent.

The team then did a cross-comparison of how much time during the exercises the correct muscle group got triggered between the two conditions. In the condition where they show the muscle engagement data in real-time, that’s the feedback. By monitoring and recording the most engagement data, the PTs reported a much better understanding of the quality of the patient’s exercise, and that it helped to better evaluate their current regime and exercise based on those stats.

“We wanted our sensing scenario to not be limited to a clinical setting, to better enable data-driven unsupervised rehabilitation for athletes in injury recovery, patients currently in physical therapy, or those with physical limiting ailments, to ultimately see if we can assist with not only recovery, but perhaps prevention,” says Junyi Zhu, MIT PhD student in electrical engineering and computer science, CSAIL affiliate, and lead author on a new paper about MuscleRehab. “By actively measuring deep muscle engagement, we can observe if the data is abnormal compared to a patient’s baseline, to provide insight into the potential muscle trajectory.”

Current sensing technologies focus mostly on tracking behaviors and heart rates, but Zhu was interested in finding a better way than electromyography (EMG) to sense the engagement (blood flow, stretching, contracting) of different layers of the muscles. EMG only captures muscle activity right beneath the skin, unless it’s done invasively.

Zhu has been digging into the realm of personal health-sensing devices for some time now. He’d been inspired by using EIT, which measures electrical conductivity of muscles, for his project in 2021 that used the noninvasive imaging technique to create a toolkit for designing and fabricating health and motion sensing devices. To his knowledge, EIT, which is usually used for monitoring lung function, detecting chest tumors, and diagnosing pulmonary embolism, hadn’t been done before.

With MuscleRehab, the EIT sensing board serves as the “brains” behind the system. It’s accompanied by two straps filled with electrodes that are slipped onto a user’s upper thigh to capture 3D volumetric data. The motion capturing process uses 39 markers and a number of cameras that sense very high frame rates per second. The EIT sensing data shows actively triggered muscles highlighted on the display, and a given muscle becomes darker with more engagement.

Currently, MuscleRehab focuses on the upper thigh and the major muscle groups inside, but down the line they’d like to expand to the glutes. The team is also exploring potential avenues in using EIT in radiotherapy in collaboration with Piotr Zygmanski, medical physicist at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute and Associate Professor of Radiation at Harvard Medical School.

“We are exploring utilization of electrical fields and currents for detection of radiation as well as for imaging of the of dielectric properties of patient anatomy during radiotherapy treatment, or as a result of the treatment,” says Zygmanski. “Radiation induces currents inside tissues and cells and other media — for instance, detectors — in addition to making direct damage at the molecular level (DNA damage). We have found the EIT instrumentation developed by the MIT team to be particularly suitable for exploring such novel applications of EIT in radiotherapy. We are hoping that with the customization of the electronic parameters of the EIT system we can achieve these goals.”

MuscleRehab Video

“This work advances EIT, a sensing approach conventionally used in clinical settings, with an ingenious and unique combination with virtual reality,” says Yang Zhang, assistant professor in electrical and computer engineering at the UCLA Samueli School of Engineering, who was not involved in the paper. “The enabled application that facilitates rehabilitation potentially has a wide impact across society to help patients conduct physical rehabilitation safely and effectively at home. Such tools to eliminate the need for clinical resources and personnel have long been needed for the lack of workforce in healthcare.”

Reprinted with permission of MIT News” (http://news.mit.edu/)

Elon Musk’s Smoking New Product

Image Credit: DonkeyHotey (Flickr)

Elon Musk’s Hair-Brained Ideas are Very Marketable

If your last name was Musk and one of your companies created a perfume, what would you name it? Perhaps Eau de Elon, or S3XY, an outlandish guess would be Neurastink, or simply Elon’s Musk. Here’s a hint, Musk’s perfume is a product of The Boring Company, the company that builds tunnels to enable rapid point-to-point transportation. Before this fragrance thrower, the company’s only other product was a flame thrower. So naturally, the company decided to call their new perfume, Burnt Hair. And it has already sold $1,000,000 worth.

Image: The Boring Company

A bottle of what his company referred to as ‘the essence of repugnant desire,’ will set you back about Ð1,666 or $100 USD. That’s if you buy it online. There is now an Ebay aftermarket where resellers are looking to fetch up to Ð16,666 for the product that was only released this week – 10,000 bottles of Burnt Hair have already been sold as of Wednesday morning.

“Just like leaning over a candle at the dinner table, but without all the hard work” – Boring Company Website

Image: The Boring Company

When he’s not tunneling, launching rockets, reinventing things on four wheels, neuralinking, or tweeting, Musk does keep busy with other strokes of brilliance. Did you know that in 2020 Tesla (TSLA) launched its own brand of tequila? That year Tesla, the world’s most valuable automaker,  also offered limited edition satin short-shorts.

Image Credit: Tesla

It isn’t clear what the inspiration was for this new product entry; developing a perfume that has earned revenue of $1,000,000 within a couple of days of launch is quite a feat, although certainly easier than colonizing Mars, and buying a microblogging social media company. Two things on Musk’s To-Do list that he seems to have fallen behind on.  

The Boring Company product page doesn’t say whether the fragrance is a limited edition item – just in time for Halloween or a long-term offering from The Boring Company. Something more exciting than a company that usually just sells holes in the ground.

Paul Hofman

Managing Editor, Channechek

Sources

https://www.boringcompany.com/burnthair

https://www.reuters.com/lifestyle/oddly-enough/elon-musk-sells-1-million-worth-quirky-new-perfume-burnt-hair-2022-10-12/

https://twitter.com/elonmusk/status/ShortShorts

Uses for Blockchain Beyond Crypto are Growing

Christian Bucad (Flickr)

Why Blockchain Could Mean Fewer Hassles for Students and Workers Proving their Credentials

Microcredentials — attestations of proficiency in a specific skill or knowledge base that are certified by an authority — can provide evidence of a person’s skills to employers.

While microcredentials are becoming more popular, the concept is hardly new: A driver’s license or the St. John Ambulance certificate could be considered as microcredentials, attesting respectively to a person’s driving skill or their competency in administering first aid.

Blockchain technology is appropriate for microcredential implementation. Blockchain can best be described as a digital ledger that records information that can be shared among a community of users. Bitcoin and other crypto-currencies are the best-known examples of blockchain, but blockchain has uses beyond financial transactions.

Student records stored in blockchain for security limit access only to legitimate users, such as institutional administrators and potential employers selected by students or job seekers. Traditionally, institutions own and control certifications like degrees, but that could shift with “digital degrees” and microcredentials that rely on blockchain.

Verifying Accomplishments

Besides providing effective security and privacy for users, blockchain can also facilitate the maintenance and dissemination of the credentials, while ensuring that access is readily available for students under their control.

Because of its immutability, blockchain can be used to attest to and verify students’ accomplishments. This is important for students seeking to have their credits recognized, whether because they are studying to obtain new professional accreditation, studying in multiple institutions or because they are moving for study or employment.

Blockchain is distributed, meaning that multiple copies of the same information are stored on different computers. So, blockchain is not controlled by any central authority and the “blocks” in the “chain,” linked chronologically, are shared in a P2P (peer-to-peer) network, which can be accessed from any node or point on the network.

These blocks are immutable, as any change to the original leaves the first iteration intact and accessible.

When students or job seekers want to have credits transferred between institutions, gatekeepers — for example, post-secondary institutions or employers — typically insist on receiving copies of diplomas and degrees directly from each institution. As more students gain credentials from multiple institutions, this process becomes increasingly untenable.

Students need to control this process and blockchain can provide a solution.

Securely Validates Learning

In 2019, McMaster University announced it was awarding “digital degrees” using blockchain to Faculty of Engineering students after the university implemented microcredentials using blockchain to securely validate students’ learning.

Some post-secondary institutions are implementing pilot projects with eCampus Ontario and industry partners to award microcredentials using blockchain.

Microcredentials are now offered by post-secondary institutions, sometimes in partnership with corporations to target labor market needs. These may come in the form of “digital badges.” Digital badges are easily verifiable testaments to when, where and how skills have been mastered. Metadata in digital badges allows viewers to click on the badge to learn things like criteria for earning the badge, the date it was issued or when it expires.

Maintaining Privacy of Data

Certification by blockchain begins when a trusted institution issues the microcredential and creates a blockchain. The student then sends a public key password to the institution, requesting a transcript be sent to a potential employer.

The institution then adds a block onto the blockchain and sends the micro-credential, which is verified and forwarded to the potential employer. The learners can keep private keys to their credentials in an offline digital wallet.

Maintaining the privacy of the data is essential. With blockchain, the ownership of the microcredential rests with the individual, not the institution.

Blockchain supports more control for students and has the capability of further democratizing education. It empowers students to maintain control of their now-secure credentials and allows them to be confident their acquired skills and knowledge will be valued.

Potential Concerns

However, there are some ethical and logistical concerns. Right now, when a person seeks to transfer credits through traditional channels, they can choose which documents or certifications to share with employers: mistakes or aspects of one’s past credentials and experience deemed less salient or undesirable can be addressed or ignored.

But blockchain is immutable and this immutability can cause its own problems when mistakes cannot be erased.

Students cannot omit blocks from the chain that they do not feel are appropriate or that could damage their reputation. So, how can they create different narratives for diverse purposes or highlight and/or hide different experiences? What happens if someone wants or needs to start anew? Is there a right to forget?

What if a student loses their key? The New York Times reports that lost passwords have locked millionaires out of their bitcoin fortunes. Will students and workers fare any better when it comes to academic and professional records? Who will respond to these problems within institutions?

These are questions post-secondary institutions and our society at large will increasingly need to navigate.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Rory McGreal, Professor and UNESCO/ICDE Chair in Open Educational Resources, Athabasca University.